BACKGROUND: There has been much evidence in recent years that free oxygen radicals and nitric oxide (NO) may play an important role in the pathophysiology of neuropsychiatric disorders. In this study, we aimed to investigate whether NO, xanthine oxidase (XO), superoxide dismutase (SOD), and adenosine deaminase (ADA) levels are associated with major depression (MD) and to evaluate the impact of antidepressant treatments on NO, SOD, ADA and XO levels in MD. METHODS: Thirty-six patients who were diagnosed as MD according to DSM-IV criteria and 20 healthy controls were included. The serum levels of NO, XO, SOD, and ADA were measured by spectrophotometric methods both in patients and controls. Patients were treated with antidepressant drugs for 8 weeks. All patients were assessed by Hamilton Depression Rating Scale (HDRS) both before and after antidepressant treatment. RESULTS: ADA and XO levels of the patients were significantly higher than the controls. SOD level of the patients was significantly lower than the controls. Although NO levels of the patients were higher than the controls, the difference was not statistically significant. There was no correlation between HDRS and the parameters studied (SOD, ADA, XO, and NO) of the patients. After 8 weeks of antidepressant treatment, ADA and SOD activities were increased, whereas NO and, XO levels decreased significantly. CONCLUSIONS: ADA, XO, and SOD activity may have a pathophysiological role in MD and may predict prognosis of MD. Activity of these enzymes may be used to monitor effects of the antidepressant treatment.
BACKGROUND: There has been much evidence in recent years that free oxygen radicals and nitric oxide (NO) may play an important role in the pathophysiology of neuropsychiatric disorders. In this study, we aimed to investigate whether NO, xanthine oxidase (XO), superoxide dismutase (SOD), and adenosine deaminase (ADA) levels are associated with major depression (MD) and to evaluate the impact of antidepressant treatments on NO, SOD, ADA and XO levels in MD. METHODS: Thirty-six patients who were diagnosed as MD according to DSM-IV criteria and 20 healthy controls were included. The serum levels of NO, XO, SOD, and ADA were measured by spectrophotometric methods both in patients and controls. Patients were treated with antidepressant drugs for 8 weeks. All patients were assessed by Hamilton Depression Rating Scale (HDRS) both before and after antidepressant treatment. RESULTS: ADA and XO levels of the patients were significantly higher than the controls. SOD level of the patients was significantly lower than the controls. Although NO levels of the patients were higher than the controls, the difference was not statistically significant. There was no correlation between HDRS and the parameters studied (SOD, ADA, XO, and NO) of the patients. After 8 weeks of antidepressant treatment, ADA and SOD activities were increased, whereas NO and, XO levels decreased significantly. CONCLUSIONS: ADA, XO, and SOD activity may have a pathophysiological role in MD and may predict prognosis of MD. Activity of these enzymes may be used to monitor effects of the antidepressant treatment.
Authors: Bárbara Tagliari; Cristie G Noschang; Andréia G K Ferreira; Otávio A Ferrari; Luciane R Feksa; Clovis M D Wannmacher; Carla Dalmaz; Angela T S Wyse Journal: Metab Brain Dis Date: 2010-05-27 Impact factor: 3.584
Authors: Michael Maes; Zdenĕk Fišar; Miguel Medina; Giovanni Scapagnini; Gabriel Nowak; Michael Berk Journal: Inflammopharmacology Date: 2012-01-24 Impact factor: 4.473
Authors: Rafael T de Sousa; Marcus V Zanetti; Geraldo F Busatto; Margaret G Mouro; Carlos A Zarate; Wagner F Gattaz; Elisa M Higa; Rodrigo Machado-Vieira Journal: J Psychiatr Res Date: 2014-04-12 Impact factor: 4.791
Authors: Ronise M Santiago; Janaína Barbiero; Bruno J Martynhak; Suelen L Boschen; Luisa M da Silva; Maria F P Werner; Claudio Da Cunha; Roberto Andreatini; Marcelo M S Lima; Maria A B F Vital Journal: J Neural Transm (Vienna) Date: 2014-01-24 Impact factor: 3.575
Authors: Julie A Pasco; Lana J Williams; Felice N Jacka; Nicole Stupka; Sharon L Brennan-Olsen; Kara L Holloway; Michael Berk Journal: Curr Osteoporos Rep Date: 2015-10 Impact factor: 5.096